Moreover, HPD has been observed following the initiation of other treatment modalities including chemotherapy [17], RAF inhibition in KRAS mutated NSCLC, and crizotinib in anaplastic lymphoma [31, 32]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.